TITLE

Many FDA-approved drug trial results remain unpublished

AUTHOR(S)
Adams, Stacey L.; Haigh, Christen; Harris, Jason; Shafer, Emily
PUB. DATE
October 2008
SOURCE
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p36
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on results of a cohort study of trials supporting new drugs approved by the U.S. Food & Drug Administration between 1998 and 2000. The study shows that results from more than half of these trials are not available in the medical literature. In multivariate logistic regression, publication correlated with statically significant results and larger sample size for pivotal trials five years post-approval, according to the findings.
ACCESSION #
34781573

 

Related Articles

  • FDA Approvals In December.  // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p6 

    A chart is presented that lists the drugs approved by the U.S. Food and Drug Administration (FDA) in December 2010, Cubicin from Cubist Pharmaceuticals Inc. and Fortesta from Endo Pharmaceuticals Inc.

  • Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation. Rising, Kristin; Bacchetti, Peter; Bero, Lisa // PLoS Clinical Trials;Nov2008, Vol. 5 Issue 11, p1561 

    Background Previous studies of drug trials submitted to regulatory authorities have documented selective reporting of both entire trials and favorable results. The objective of this study is to determine the publication rate of efficacy trials submitted to the Food and Drug Administration (FDA)...

  • Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results. An-Wen Chan // PLoS Clinical Trials;Nov2008, Vol. 5 Issue 11, p1533 

    The article dicusses research being done on reporting bias in clinical drug trials. It references the study "Reporting Bias in Drug Trials Submitted to the Food and Drug Administration (FDA): A Review of Publication and Presentation" by Lisa Bero et al published in the same issue. Trials from 33...

  • WASHINGTON INSIDER: Update.  // Medical Marketing & Media;Jun2008, Vol. 43 Issue 6, p17 

    The article offers news briefs related to the U.S. Food and Drug Administration (FDA) agency. The FDA's latest annual report shows that 71% of pending postmarketing study commitments promised by drug sponsors at the time of approval were never started. FDA identified 20 prescription drugs and...

  • Savient Prices Offering: $53M for Gout Drug.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p2 

    The article reports that East Brunswick, New Jersey-based Savient Pharmaceuticals Inc. has increased the price offer for the shares of its gout drug Krystexxa. It mentions that proceeds will be used for the issues related to the drug's response letter and for finding a secondary supplier of...

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Mar2013, Vol. 48 Issue 3, p243 

    Several tables of new drugs and dosage forms, and drug agents approved by the U.S. Food and Drug Administration (FDA) in December 2012 are presented.

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Sep2013, Vol. 48 Issue 8, p682 

    Several tables are presented offering drug related information released by the U.S. Food and Drug Administration's (FDA) during May 18-July 17, 2013 including one on drug approvals by the FDA, another on new drug dosage forms, and other on the filing of new drug license applications.

  • Abridged Study to Haunt CTI? FDA Questions Pixantrone Data. Boggs, Jennifer // BioWorld Today;2/9/2010, Vol. 21 Issue 26, p1 

    The article reports on the decline in shares of Cell Therapeutics Inc. following the release of briefing documents from the U.S. Food and Drug Administration (FDA), which indicated that the firm's abbreviated pivotal study of its pixantrone may not be sufficient in earning approval for the...

  • From Molecule to Medicine Cabinet: A Drug's Long Journey from Development to Approval. Onofrey, Bruce E. // Review of Optometry;Jun2013, Vol. 150 Issue 6, p26 

    The article focuses on the drug approval process of the U.S. Food and Drug Administration. It states that first step is preclinical studies in which the molecule is tested on animals and then an Investigational New Drug Application (IND) is filed to FDA to get approval for starting clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics